Colorectal cancer (CRC) is the second leading cause of cancerrelated death in the United States [1] . Screening with guaiacbased fecal occult blood testing (gFOBT) [2] or sigmoidoscopy [3] decreases CRC incidence and mortality, and greater benefits are expected from fecal immunochemical testing (FIT) [4] [5] [6] [7] and colonoscopy [8] [9] [10] [11] .
screening under a health-care sector perspective [14] . First, we examined the implications of differences in prices paid by different types of insurers. Payments by commercial insurers, who cover the vast majority of people under age 65, often substantially exceed Medicare payment rates [15] [16] [17] .
Second, commercial insurers and Medicare have different time horizons due to the transition in coverage at age 65. Because most CRCs arise from adenomas or serrated lesions over many years [18, 19] , the removal of CRC precursors between ages 50 and 64 may translate into prevented CRCs once people become Medicare beneficiaries at ages 65 and older. Thus, commercial insurers may bear the screening costs that yield benefits under Medicare in the form of increased quality-adjusted life-years (QALYs) as well as reductions in spending for CRC care.
Our aims were to assess the implications of differential payment levels between commercial insurers and Medicare when assessing the cost-effectiveness of CRC screening from the insurer, third-party payer perspective, considering insurer-specific time horizons, and to evaluate the distribution of costs and benefits of CRC screening between commercial insurers and Medicare in analyses with lifetime perspectives. Given our aims, we focused primarily on the incremental costs/QALY gained by screening vs. no screening under various scenarios, but we also report the incremental costs/QALY gained between competing screening strategies.
MEthodS

General study design
We conducted a cost-effectiveness analysis under a health-care sector perspective as recommended by the Second Panel on Cost-Effectiveness in Health and Medicine, but focusing on CRCrelated screening, complication, and treatment costs (Impact Inventory, Supplement) [14] . Given our aims, a comprehensive societal perspective analysis [14] was not applicable in this study.
We adapted our validated decision analytic Markov cohort model of CRC screening in the general US population [20, 21] to explore screening under differential payment rates for persons under age 65 (reflecting commercial insurance payments) vs. age ≥65 (reflecting Medicare payments). We modeled several currently established and accepted screening strategies [22, 23] , including annual FOBT or FIT, sigmoidoscopy every 5 years (FS), colonoscopy every 10 years (COLO), FS/FOBT, and FS/FIT, with screening eligibility from age 50 until age 80 (the mid-point of the age range 76-85 for which the U.S. Preventive Services Task Force recommends individualizing screening decisions) [22] . Based on the results of randomized controlled trials, we assumed that the mortality benefit of flexible sigmoidoscopy was restricted to the distal colon and rectum [24] [25] [26] .
We did not consider computed tomography (CT) colonography or a multi-target stool DNA assay [22] , or methylated Septin 9 DNA because we did not have detailed primary data on commercial payments for these tests. However, we have previously considered the potential cost-effectiveness of these modalities [20, [27] [28] [29] [30] .
We explored six screening scenarios representing different combinations of time horizons, compliance with recommended screening, and payment rates by age ( Table 1) 
Decision analytic model and time horizons of simulations
Our original model, data sources, and validations against the Minnesota Colon Cancer Control Study [31, 32] , United Kingdom Flexible Sigmoidoscopy Trial [24] , SCORE Trial [25] , and PLCO Cancer Screening Trial [26] have been detailed previously [20, 21, 29] ( Supplementary Figure 1 and Table 2 In our first set of analyses, persons entered the model at age 50 and screening and surveillance were offered from age 50 to 80, with persons followed until death (age 100 maximum) (analyses with "Lifetime Horizon, " Table 1 ). In our analyses reflecting the "Commercial Perspective" only ( Table 1) , persons entered the model at age 50 and screening and surveillance could be offered from age 50 to 64, with persons followed until age 64 or death. In our analyses reflecting the "Medicare Perspective" only ( Table 1) , persons entered the model at age 65, either previously screened or unscreened, and were followed until age 100 or death, either with or without screening under Medicare at ages 65-80 ( Table 1) . The primary analyses included both genders. We performed analyses stratified by gender to explore scenarios in which cost-effectiveness differed by gender.
Cost inputs
Payment rates were derived from national average Medicare reimbursement rates [33] [34] [35] [36] [37] and CRC care costs [38] for persons age ≥65, and from commercial payment rates for colorectal testing in persons aged 50-64 [15] , accounting for colonoscopy site of service [15, 38] . The rates include the insurer and patient liabilities associated with the service. In the base case, we measured payment rates in 2009 dollars, reflecting the year from which commercial payment data were available [15] . In sensitivity analyses, we updated cost inputs to 2015 dollars; we used the year-specific new Medicare rates, and updated all other costs by the medical component of the consumer price index ( Table 2 and Supplement). Based on our observed mean ratio of commercial to Medicare payment rates for colorectal tests of 1.35 [15] , we assumed base case CRC care and complication costs for persons aged 50-64 that were 1.35-fold those of persons age ≥65, and we varied this in sensitivity analyses.
Clinical and economic outcomes
The principal model outputs were quality-adjusted life-years (QALYs) and costs per person [13, 39] . Future QALYs and costs were discounted by 3% annually [40] . Health state utilities for CRC by stage ( Table 2 ) were used to calculate QALYs by applying these for 5 years after CRC diagnosis. We estimated CRC cases by stage and CRC deaths, and lifetime number of tests/person in cohorts of 100,000 persons.
Cost-effectiveness analyses
Analyses from the perspective of the third-party payers were performed in TreeAge Pro (TreeAge Software, Inc., Williamstown, MA) and Excel 2010 (Microsoft Corporation, Redmond, WA), reflecting a hybrid-payer longitudinal perspective as well as time horizon-specific perspectives for commercial insurers and Medicare as detailed above. Incremental cost-effectiveness ratios (ICERs) were calculated [13, 39] . In discussing whether strategies were "cost-effective, " we adopted the commonly used willingnessto-pay threshold of $100,000/QALY gained, but because there is no universal consensus on a threshold, we emphasize costs/QALY gained.
Sensitivity analyses (one-way and on grouped sets of related variables) were used to examine all model inputs. We considered the potentially higher costs of lower endoscopy when anesthesiarelated costs are incurred, as observed in our recent study [15] . In threshold analyses, we examined test cost requirement to achieve costs of $100,000/QALY gained. We performed probabilistic Monte Carlo simulations with 10,000 trials. In the first Monte Carlo simulation, we varied only commercial payment rates within the distributions observed in our recent study [15] . In a second Monte Carlo simulation, we varied all model inputs simultaneously, with commercial payments rates as in the first simulation, and using beta distributions for probabilities derived from means, standard deviations and ranges in the literature [41] . For commercial payment inputs, we used gamma distributions, with means and standard deviations [15] used to approximate alpha and lambda. Costs of screening under Medicare were varied together within a range of ±20% of the base case value, and costs of care were varied together but independently from costs of screening within a range of ±20%.
rESultS
Lifetime horizon -insurer-specific rates
Under a single long-term time horizon spanning ages 50 until death, with screening for ages 50-80 with commercial payment rates for ages 50-64 and Medicare rates for ages ≥65 ("Lifetime Horizon -Insurer-Specific Rates"), FOBT and FIT The American Journal of GastroenteroloGy www.nature.com/ajg Large polyp, % 5 [48, 50, 51] Annual transition rate to small polyp from normal, % Age specific, 1.1-1.9 [47] [48] [49] [50] [51] Annual transition rate to large polyp from small polyp, % 1.5 [48, 50, 51] Annual transition rate to cancer without polypoid precursor, % Age specific, 0.006-0.086 [47-49, 52, 53] Annual transition rate to cancer from large polyp, % 5 [47-49, 52, 53] Symptomatic presentation of localized cancer, % 22/y over 2 y [53] Symptomatic presentation of regional cancer, % 40/y over 2 y [53] Mortality rate from treated localized cancer, % 1.74/y in first 5 y [53] Mortality rate from treated regional cancer, % 8.6/y in first 5 y [53] Mean survival from distant cancer, y 1.9 [53, [54] [55] [56] [57] [58] [59] [60] Mortality rate from cancer treatment, % 2 [52, 61] Test performance characteristics and complications
FOBT sensitivity for cancer, % 40 (25-50) [38, 62] FOBT sensitivity for large polyp, % 11 (9-28) [38, 62] FOBT sensitivity for small polyp, % 5 (5-14) [38, 62] FOBT specificity, % 97 (95-99) [38, 62] FIT sensitivity for cancer, % 70 (50-87) [ Fig. 1a and Table 3 ).
In incremental comparisons between strategies, FOBT and FIT were both more effective and less costly than FS, and FIT was more effective and less costly than COLO; FIT cost $22,400/QALY
Variable Base case value (range) a, b References
Sigmoidoscopy 287 [15] Sigmoidoscopy with biopsy 801 [15] Anesthesia for sigmoidoscopy 545 [15] Colonoscopy 1193 [15] Colonoscopy with lesion removal 1596 [15] Anesthesia for colonoscopy 538 [15] Major hemorrhage after sigmoidoscopy or colonoscopy 7891 [15, 75, 76] Perforation after sigmoidoscopy or colonoscopy 21,383 [15, 75, 76] Colorectal cancer care by stage
Localized, initial 37,105 [15, 38] Localized, continuing yearly 2952 [15, 38] Localized, colorectal cancer death 66,516 [15, 38] Regional, initial 62,434 [15, 38] Regional, continuing yearly 3934 [15, 38] Regional, colorectal cancer death 69,890 [15, 38] Distant, initial 81,528 [15, 38] Distant, colorectal cancer death 93,798 [15, 38] Costs, Medicare payments for persons age 65 and older, $ b
FOBT 5 [33] FIT 23 [33] Sigmoidoscopy 234 [34, 36, 37] Sigmoidoscopy with biopsy 428 [34, 36, 37] Colonoscopy 677 [34, 36, 37] Colonoscopy with lesion removal 871 [34, 36, 37] Major hemorrhage after sigmoidoscopy or colonoscopy 5845 [34, 35] Perforation after sigmoidoscopy or colonoscopy 15,840 [34, 35] Colorectal cancer care by stage Localized, initial 27,485 [38] Localized, continuing yearly 2187 [38] Localized, colorectal cancer death 49,271 [38] Regional, initial 46,248 [38] Regional, continuing yearly 2914 [38] Regional, colorectal cancer death 51,770 [38] Distant, initial 60,391 [38] Distant, colorectal cancer death 69,480 [38] FOBT fecal occult blood testing, FIT fecal immunochemical testing, SD standard deviation a In sensitivity analyses, commercial test costs were varied as low as the 25%-ile and as high as the 90%-ile of reported payments in our previous study [15] . In Monte Carlo simulation, commercial test costs were varied within gamma distributions, with means and standard deviations [15] used to approximate alpha and lambda. Treatment and complication costs were varied as a multiple of Medicare costs, as described in the "Methods" b
In Monte Carlo simulation, Medicare test costs were varied by a common factor within a range of ±20% of the base case value, and costs of care by an independent common factor also within a range of ±20% Fig. 1a and Table 3 ).
Lifetime horizon -Medicare rates
The lifetime costs/person with screening were 20-44% higher when applying commercial payments rates for people aged 50-64 ("Lifetime Horizon -Insurer-Specific Rates, " above) than when applying Medicare rates for all ages ("Lifetime Perspective -Medicare Rates") ( Table 3 ). With Medicare rates for all ages, FOBT and FIT were cost-saving relative to no screening, and other strategies cost ≤$7,000/QALY gained ( Table 3) . FIT continued to be more effective and less costly than FS and COLO ( Fig. 1b vs. Fig. 1a and Table 3 ).
Commercial insurer perspective
Under a restricted time horizon spanning ages 50-64 and commercial payment rates ("Commercial Perspective"), no strategy was cost-saving and each strategy was less cost-effective than under either lifetime horizon. FOBT and FIT cost <$61,000/QALY gained; FS, FS/FOBT, and FS/FIT cost <$140,000/QALY gained; and COLO cost $189,000/QALY gained ( Table 4 and Fig. 2a) . The costs/QALY gained were more favorable for men ( Supplementary   Table 3A ) than for women ( Supplementary Table 3B ), but COLO remained relatively costly at $139,000/QALY gained.
Medicare perspective: continuing screening in those previously screened
Under a restricted time horizon spanning ages ≥65, and assuming that persons entering Medicare had been screened previously under commercial insurance ("Medicare Perspective -Screened Ages 50-64"), continuing FOBT and FIT were more effective and less costly than stopping screening; continuing COLO, FS/FOBT, and FS/FIT cost <$30,000/QALY gained compared with stopping screening; and continuing FS cost $53,600/QALY gained compared with stopping screening ( Table 4 and Fig. 2b) . The results did not differ substantively by gender ( Supplementary Tables 3A  and 3B ).
Medicare perspective: initiating screening in those previously unscreened
Under a restricted time horizon spanning ages ≥65, and assuming that persons entering Medicare never had been screened previously under commercial insurance ("Medicare Perspective -Unscreened Ages 50-64"), initiating any screening strategy was more effective (mean 0.0337-0.0557 QALYs gained/person, depending on the screening strategy) and was cost-saving (mean $137-$755 saved/person, depending on the screening strategy) compared with not initiating screening ( Table 4 and Fig. 2c) . This pattern applied to all strategies for both genders ( Supplementary  Tables 3A and 3B ).
Medicare perspective: benefits to Medicare of screening under commercial insurance
In persons entering Medicare having been screened previously under commercial insurance at ages 50-64, but then not continuing screening under Medicare ("Medicare Perspective -Screened Ages 50-64 and Not 65-80"), the previous screening under commercial insurance yielded substantial gains in QALYs/person (mean 0.0605-0.0976 QALYs gained/person, depending on the screening strategy) as well as cost-savings (mean $750-$1234 saved/person, depending on the screening strategy) for Medicare at ages ≥65 ( Table 4 and Fig. 2d ). This pattern applied to all strategies for both genders (Supplementary Tables 3A and 3B) .
Sensitivity analyses
The most influential variables on the cost/QALY gained by screening were the commercial payment rates ( Supplementary Table 1) .
Varying test performance characteristics, complication rates, utilities, and the cost of complications and CRC care, adding anesthesia costs to lower endoscopy, and updating costs to 2015 dollars had minimal impact on the results (Supplementary Table 1) .
Focusing on the commercial insurer perspective with a restricted time horizon spanning ages 50-64 and commercial payment rates, we calculated test costs at which COLO would be considered cost-effective relative to no screening at a threshold of <$100,000/ QALY gained. The resulting private insurer costs for colonoscopy and colonoscopy with lesion removal were $759 and In a Monte Carlo simulation of the "Lifetime Horizon -Insurer-Specific Rates" scenario in which only commercial payments were varied within the distributions observed in our recent study [15] Supplementary Table 2 . The 10-90th percentile ranges around the median costs/QALY gained were narrow and the conclusions were not affected. From the perspective of commercial insurers with a restricted time horizon of ages 50-64, screening gained fewer QALYs at higher cost/ QALY gained for all modalities except colonoscopy than did continuing screening from the perspective of Medicare in those ages 65-80. There remained substantial gains in QALYs and substantial cost-savings by Medicare at ages 65-100 that were attributable to screening under commercial insurance at ages 50-64. Instituting screening at age 65 under Medicare in those previously unscreened under commercial insurance remained highly effective and costsaving for all strategies.
dIScuSSIon
This study of colorectal neoplasia screening in the United States focuses on the effects of differences between commercial insurer and Medicare payment rates and time horizons on the cost-effectiveness of screening using a health-care sector perspective. Many cost-effectiveness analyses have used Medicare rates for cost inputs over a lifetime, but this does not account for the higher reimbursement rates often paid by commercial insurers, or the different time horizons for commercial insurers and Medicare.
We found that for a time horizon of age 50 until death, the estimated cost per person of screening was 20-44% higher, depending on the screening modality, when conducting the analysis using commercial rather than Medicare payment rates for health care used by people under the age 65. While accounting for commercial payments at ages 50-64 increased the costs of all strategies, FOBT and FIT remained cost-saving, and colonoscopy remained highly cost-effective compared with no screening ($15,000/QALY gained when commercial costs were considered, compared with $3,400/QALY gained when Medicare rates were used for all ages).
Our analyses of restricted time horizons reflecting the differing perspectives of commercial insurers and Medicare demonstrate how the costs and benefits of lifetime screening are distributed across different types of insurance. Restricting the time horizon For hypothetical cohorts with optimal (100%) participation (uptake and adherence). "Dominates" means more effective and less costly than the comparator. to ages 50-64, we found that screening under commercial insurance generated fewer additional QALYs/person during ages 50-64 with all modalities, except colonoscopy, than continuing screening for ages 65-80 under Medicare. From the perspective of commercial insurers, the cost/QALY gained of endoscopic screening was high if the impact on CRC outcomes was only counted for ages 50-64, at a willingness-to-pay threshold of $100,000/QALY gained. However, prior screening at ages 50-64 yielded gains in QALYs at ages 65-100 that were several-fold higher than those realized before age 65, and Medicare-derived substantial savings for CRCs prevented by screening and polypectomies at ages 50-64 under commercial insurance. In those previously unscreened, initiating screening under Medicare for ages 65-80 was highly effective, yielding gains in QALYs/person that were several-fold higher than those resulting from continuing screening under Medicare in previously screened persons. Furthermore, initiating screening at age 65 under Medicare was cost-saving for all modalities. Our analysis points to the importance of considering a lifetime perspective when using cost-effectiveness analysis to inform coverage decisions. Only FOBT and FIT were cost-effective relative to no screening using conventional thresholds (cost/QALY gained ≤$100,000) when evaluated from the commercial insurer perspective with a time horizon of ages 50-64. This analysis, however, by definition does not consider the longer-term benefits of screening. Making decisions based on this truncated time horizon could result in the inappropriate conclusion that services that are cost-effective but characterized by short-term costs and long-term benefits should be excluded from coverage. Similar issues arise in other settings. For example, should state Medicaid programs assess the effectiveness and cost-effectiveness of vaccinations among children over a time horizon of only a few years for those who subsequently transition to private insurance?
In this study, we did not explicitly examine the overall effect of switching between different screening modalities over a lifetime. These types of analyses have been conducted in other studies. We have previously found that FIT screening starting at age 50 and converting to colonoscopy at age 55 is likely to be highly cost-effective in Germany [42] . A previous US-based simulation estimated that FIT beginning at age 50 and then a single colonoscopy at age 66 delivers clinical and economic outcomes similar to those of single-modality strategies, with a favorable impact [43] . While it may be tempting to conclude, based on our results for payer-specific time horizons, that stool-based screening of younger adults followed by colonoscopy at older ages may be an optimal strategy, the strategies that are most cost-effective for particular payers based on a truncated time horizon do not necessarily represent the most cost-effective mixed modality strategy when analyzed over a lifetime perspective. Modeling such hybrid strategies was beyond the scope of the current study. Our analyses extend the observations from previous studies. In a previous modeling study we found that, compared with national screening uptake of 40% for ages 50-80, screening 75% of the US population for ages 50-80 increased annual costs related to CRC care and testing from $3.6 billion to $5.0 billion for 50-64-year olds, but decreased annual costs from $5.9 billion to $5.6 billion for those aged 65 years and older [44] . However, in that study, the costs for commercial payers were likely underestimated, as we did not account for differential payment rates by commercial insurers.
More recent analyses similarly concluded that increased screening participation in the pre-Medicare population could reduce CRC incidence and mortality, with the additional screening costs largely offset by long-term Medicare treatment savings [45, 46] . In the first study, the unit costs for screening procedures and CRC treatments in the pre-Medicare privately-insured population were assumed to be 40% higher than in the Medicare population, with 74% of the pre-Medicare population insured by private insurance, and the rest by Medicaid or Medicare, or uninsured [45] . The second study focused on colonoscopy, and adopted a cost perspective of a private insurer and a value perspective that included survival past age 65 years [46] . Our current analysis focused specifically on commercial payers before age 65, informed by actual payment rates by commercial insurers, and considered different time horizons as well as the commercial vs. Medicare perspectives [15] .
Our study has limitations. First, we did not examine differential participation rates between strategies because that was not the focus of these analyses. We refer interested readers to our previous detailed explorations of this topic [29, 30] . Second, we did not consider complex scenarios in which persons could be screened with one modality under commercial insurance, and then with a different modality under Medicare at ages 65-80. Third, while we used primary data for commercial payments for screening tests, we did not have such data available for CRC care or complications, and instead we made assumptions about the ratio of commercial to Medicare payments for those categories of costs. However, varying those assumptions within reasonable ranges did not affect our conclusions. Fourth, we did not capture more recent reductions in Medicare payments for endoscopic services occurring in 2016 and 2017, but this would make screening even more attractive from the perspective of Medicare. Fifth, a comprehensive analysis including future costs unrelated to CRC, or accounting for time, transportation and non-health-care costs [14] was beyond the scope of this study. Sixth, we did not con-sider CT colonography or the multi-target stool DNA assay in this analysis.
In summary, accounting for the higher payment rates by commercial payers compared with Medicare leads to higher but still highly acceptable estimated costs/QALY gained by colorectal neoplasia screening for ages 50-80. Commercial insurers paying for screening at ages 50-64 provide substantial clinical benefits over the lifetime of a population, but most of this benefit is realized at ages 65 and older. While Medicare derives substantial clinical and economic benefits from screening performed under commercial insurance at ages 50-64 with any of the established CRC screening methods, continuing screening is likely to yield substantial additional clinical benefit at acceptable costs, and initiating any form of screening in those previously unscreened is predicted to be highly effective as well as cost-saving. As US efforts intensify to reach the goal of screening at least 80% of eligible adults, we emphasize that multiple cost-effective screening methods are available, and that accommodating patient preferences can improve overall adherence with screening.
What are the implications of our findings for policy? Many interventions are likely to show the same delayed benefit as seen with CRC screening, including, for instance, control of hypertension, diabetes, and hypercholesterolemia. We believe that insurers should use a lifetime perspective when assessing the cost-effectiveness of covered services. Using a payer-specific perspective focused on short-term cost-effectiveness would lead to the underuse of services whose benefit is derived primarily in the distant future. For older adults under Medicare, CRC screening should remain a preventive health priority, particularly in those who have not undergone screening previously. 
Study Highlights
WhAT IS CURRENT kNOWLEDgE ✓ ✓ colorectal cancer (crc) screening decreases crc incidence and mortality and is estimated to be highly costeffective.
✓ ✓ Most crc screening cost-effectiveness analyses have used Medicare payment rates, which are substantially lower than commercial insurance rates. 
